Roberta Roncarati

Bologna, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Cancer of unknown primary genomic profiling from cell-free DNA provides insights into CUP biology and vulnerabilities.

Cancer of unknown primary genomic profiling from cell-free DNA provides insights into CUP biology and vulnerabilities.

Journal: Frontiers in medicine

Published: December 29, 2025

Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC.

Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 13, 2025

Quantification of Tissue and Circulating MicroRNAs by Droplet Digital PCR.

Quantification of Tissue and Circulating MicroRNAs by Droplet Digital PCR.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: October 10, 2025

Circular RNAs in Cardiovascular Physiopathology: From Molecular Mechanisms to Therapeutic Opportunities.

Circular RNAs in Cardiovascular Physiopathology: From Molecular Mechanisms to Therapeutic Opportunities.

Journal: International journal of molecular sciences

Published: August 27, 2025

Profibrotic Molecules Are Reduced in CRISPR-Edited Emery-Dreifuss Muscular Dystrophy Fibroblasts.

Profibrotic Molecules Are Reduced in CRISPR-Edited Emery-Dreifuss Muscular Dystrophy Fibroblasts.

Journal: Cells

Published: July 18, 2025

Targeting metabolic vulnerabilities: REV-ERB agonist SR9009 potentiates sorafenib efficacy in liver cancer.

Targeting metabolic vulnerabilities: REV-ERB agonist SR9009 potentiates sorafenib efficacy in liver cancer.

Journal: Cell death discovery

Published: June 25, 2025

Circulating MicroRNAs in Patients with Psoriasis Treated with Anti-IL-23: A Cohort Study.

Circulating MicroRNAs in Patients with Psoriasis Treated with Anti-IL-23: A Cohort Study.

Journal: Dermatology and therapy

Published: October 10, 2024

Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives.

Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives.

Journal: Cancers

Published: June 26, 2024

MicroRNA dysregulation in ataxia telangiectasia.

MicroRNA dysregulation in ataxia telangiectasia.

Journal: Frontiers in immunology

Published: June 05, 2024

Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary.

Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: November 05, 2023

Combining gemcitabine and MSC delivering soluble TRAIL to target pancreatic adenocarcinoma and its stroma.

Combining gemcitabine and MSC delivering soluble TRAIL to target pancreatic adenocarcinoma and its stroma.

Journal: Cell reports. Medicine

Published: May 31, 2023

ARID1A in cancer: Friend or foe?

ARID1A in cancer: Friend or foe?

Journal: Frontiers in oncology

Published: January 02, 2023

Showing 1-12 of 25

Last Updated: 09/26/2026